Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane Single-pass type II membrane protein |
Domain |
PF00431 CUB domain PF00057 Low-density lipoprotein receptor domain class A PF01390 SEA domain PF00089 Trypsin |
Function |
Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing. |
Biological Process |
GO:0001701 in utero embryonic development GO:0001763 morphogenesis of a branching structure GO:0001838 embryonic epithelial tube formation GO:0001841 neural tube formation GO:0001843 neural tube closure GO:0001890 placenta development GO:0001892 embryonic placenta development GO:0002064 epithelial cell development GO:0003382 epithelial cell morphogenesis GO:0008544 epidermis development GO:0009913 epidermal cell differentiation GO:0014020 primary neural tube formation GO:0016331 morphogenesis of embryonic epithelium GO:0021915 neural tube development GO:0030216 keratinocyte differentiation GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0043588 skin development GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0060562 epithelial tube morphogenesis GO:0060606 tube closure GO:0060669 embryonic placenta morphogenesis GO:0060670 branching involved in labyrinthine layer morphogenesis GO:0060671 epithelial cell differentiation involved in embryonic placenta development GO:0060672 epithelial cell morphogenesis involved in placental branching GO:0060706 cell differentiation involved in embryonic placenta development GO:0060711 labyrinthine layer development GO:0060713 labyrinthine layer morphogenesis GO:0061138 morphogenesis of a branching epithelium GO:0061458 reproductive system development GO:0072175 epithelial tube formation |
Molecular Function |
GO:0004175 endopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0008236 serine-type peptidase activity GO:0017171 serine hydrolase activity |
Cellular Component |
GO:0016323 basolateral plasma membrane GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane |
KEGG | - |
Reactome |
R-HSA-1266738: Developmental Biology R-HSA-6809371: Formation of the cornified envelope R-HSA-6805567: Keratinization |
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ST14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between ST14 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ST14 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ST14 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ST14 in various data sets.
|
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ST14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ST14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ST14. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ST14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ST14 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ST14 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ST14 |
Name | suppression of tumorigenicity 14 (colon carcinoma) |
Aliases | SNC19; MT-SP1; TMPRSS14; epithin; matriptase; PRSS14; ARCI11; MTSP1; TADG15; membrane-type serine protease 1 ...... |
Chromosomal Location | 11q24-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ST14 collected from DrugBank database. |
Details on drugs targeting ST14.
|